Today Cardiome Pharma Corporation Ord (NASDAQ:CRME) Reported Decrease in Shorted Shares

November 21, 2017 - By Marie Mckinney

 Today Cardiome Pharma Corporation Ord (NASDAQ:CRME) Reported Decrease in Shorted Shares

Investors sentiment increased to 0.83 in Q2 2017. Its up 0.06, from 0.77 in 2017Q1. It improved, as 5 investors sold CARDIOME PHARMA CORP shares while 7 reduced holdings. 1 funds opened positions while 9 raised stakes. 15.20 million shares or 8.53% more from 14.00 million shares in 2017Q1 were reported.
Jpmorgan Chase & stated it has 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Morgan Stanley reported 12,140 shares. Citadel Advsr Ltd Liability Corp has invested 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Deutsche State Bank Ag owns 4,169 shares or 0% of their US portfolio. Geode Mngmt Limited holds 0% in CARDIOME PHARMA CORP (NASDAQ:CRME) or 12,238 shares. Royal Bancorporation Of Canada accumulated 1,051 shares or 0% of the stock. Renaissance Techs Lc holds 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME) for 350,713 shares. Cibc Ww holds 0% or 11,370 shares in its portfolio. Knott David M reported 134,578 shares. Clough Capital Prns Lp stated it has 0.9% in CARDIOME PHARMA CORP (NASDAQ:CRME). Comml Bank Of America De reported 45 shares or 0% of all its holdings. 7,441 are held by Gp One Trading L P. Pnc Finance Svcs Group accumulated 51,400 shares. Westfield Management Lp reported 5.29M shares. Rock Springs Capital Mngmt L P stated it has 0.27% in CARDIOME PHARMA CORP (NASDAQ:CRME).

The stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered a decrease of 20.19% in short interest. CRME’s total short interest was 58,100 shares in November as published by FINRA. Its down 20.19% from 72,800 shares, reported previously. With 232,200 shares average volume, it will take short sellers 0 days to cover their CRME’s short positions. The short interest to Cardiome Pharma Corporation Ord’s float is 0.25%.

About 55,343 shares traded. CARDIOME PHARMA CORP (NASDAQ:CRME) has declined 11.02% since November 21, 2016 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has market cap of $52.04 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.


Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cardiome Pharma Corp had 13 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 14 by LB Securities. Canaccord Genuity reinitiated the shares of CRME in report on Monday, July 17 with “Buy” rating. The rating was upgraded by Mackie to “Speculative Buy” on Friday, May 6. The stock has “Hold” rating by Zacks on Wednesday, August 26. The firm has “Buy” rating given on Wednesday, June 1 by H.C. Wainwright. The rating was downgraded by Zacks to “Buy” on Tuesday, August 11. As per Wednesday, November 15, the company rating was maintained by Canaccord Genuity. On Tuesday, August 22 the stock rating was maintained by H.C. Wainwright with “Buy”. Mackie downgraded the stock to “Hold” rating in Wednesday, October 12 report. On Monday, August 21 the stock rating was maintained by Canaccord Genuity with “Buy”.

Another recent and important CARDIOME PHARMA CORP (NASDAQ:CRME) news was published by which published an article titled: “Cardiome Pharma: The Pieces Are Coming Together” on May 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.